Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Hepion Pharms Inc (HEPA)

Hepion Pharms Inc (HEPA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Hepion Pharmaceuticals In-Licenses ctRNA Biomarker Assay to Facilitate Early Diagnosis and Surveillance of Hepatocellular Carcinoma GlobeNewswire - Tue Mar 3, 6:35AM CST

Next-generation, non-invasive diagnostic platform has potential applications in solid tumor types beyond liver cancer Licensing deal reflects Hepion’s strategic shift to advancing clinically proven...

HEPA : 0.0450 (-13.63%)
Hepion Pharmaceuticals Successfully Completes Application to the OTCQB GlobeNewswire - Wed Jun 25, 2025

HEPA : 0.0450 (-13.63%)
Hepion Pharmaceuticals Announces Dr. Kaouthar Lbiati as Interim Chief Executive Officer GlobeNewswire - Mon Jun 16, 2025

HEPA : 0.0450 (-13.63%)
Hepion Pharmaceuticals Announces Receipt of Delisting Notification from Nasdaq GlobeNewswire - Mon May 12, 2025

HEPA : 0.0450 (-13.63%)
Hepion Pharmaceuticals Executes Binding Letter of Intent with New Day Diagnostics to Commercialize Diagnostic Tests for Celiac Disease, Respiratory Multiplex, H. Pylori and HCC GlobeNewswire - Wed May 7, 2025

HEPA : 0.0450 (-13.63%)
Hepion Pharmaceuticals Announces Reverse Stock Split GlobeNewswire - Fri Mar 14, 2025

HEPA : 0.0450 (-13.63%)
Hepion Pharmaceuticals Announces $9.0 Million Public Offering GlobeNewswire - Wed Jan 22, 2025

HEPA : 0.0450 (-13.63%)
Hepion Pharmaceuticals, Inc. Announces Termination of Merger Agreement with Pharma Two B Ltd. GlobeNewswire - Wed Dec 11, 2024

HEPA : 0.0450 (-13.63%)
Hepion Pharmaceuticals Urges Shareholders to Approve Merger with Pharma Two B to Enhance Investment Potential Quiver Quantitative, Inc. - Mon Dec 2, 2024

Hepion Pharmaceuticals urges shareholders to support its merger with Pharma Two B to enhance investment potential and address financial challenges.Quiver AI SummaryHepion Pharmaceuticals is urging its...

HEPA : 0.0450 (-13.63%)
Hepion Pharmaceuticals Issues Letter to Shareholders Urging Support for Proposed Merger with Pharma Two B GlobeNewswire - Mon Dec 2, 2024

HEPA : 0.0450 (-13.63%)

Barchart Exclusives

Oil Prices Crash 16% on Iran War Ceasefire—Why ExxonMobil Is Still the Only Buy That Makes Sense Barchart - 1 hour ago
Oil prices and stocks had soared on the escalation of the Iran war, but a two-week ceasefire sent them plummeting. However, regardless of whether the ceasefire holds or new hostilities break out, one oil stock is a buy no matter which way this conflict goes. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.